Shineco Announces Acquisition of Medical Device Company
MWN-AI** Summary
On March 25, 2025, Shineco, Inc. (NASDAQ: SISI) announced its strategic acquisition of a 75% equity interest in FuWang (HK) International Company Limited, a medical device company known for its research, development, manufacturing, and commercialization of Class II and III medical devices. The transaction, executed through Shineco Life Science Group Hong Kong Co., Limited, involves a total payment of approximately $8.8 million in cash, alongside the issuance of 3.4 million shares of Shineco’s common stock, and a transfer of equity interest in another subsidiary.
FuWang Company holds a robust portfolio in medical devices that includes biochemical analyzers and patient monitors, with a notable presence across several Chinese provinces. Following the acquisition, FuWang plans to leverage cloud computing and artificial intelligence to enhance healthcare delivery through integrated health management systems that connect pre-hospital and hospital care, establishing tiered treatment protocols for critical conditions.
Shineco's CEO, Jennifer Zhan, expressed optimism regarding the acquisition, highlighting the potential for immediate synergies with Shineco’s existing medical device operations. The integration of FuWang’s capabilities is expected to significantly boost Shineco’s financial performance, with projected revenue growth for FuWang set to rise from $11.03 million in 2025 to approximately $17.24 million by 2027.
This acquisition underscores Shineco’s commitment to advancing its medical device business and enhancing its market position in the healthcare industry. They encourage stakeholders to review further details of this acquisition within their SEC filings, ensuring transparency and clarity as they move forward in this strategic endeavor.
MWN-AI** Analysis
Shineco, Inc. (NASDAQ: SISI) has announced a significant acquisition that could propel it into a strong market position within the medical device sector. The company’s decision to acquire a 75% equity interest in FuWang (HK) International Company Limited for approximately $8.8 million in cash, plus additional stock, indicates a strategic move aimed at enhancing its existing medical device business.
FuWang specializes in the R&D, manufacturing, and commercialization of Class II and III medical devices, including biochemical analyzers and patient monitors. This acquisition is expected to create immediate synergies with Shineco’s current product offerings and operational capabilities. With FuWang's established sales network across multiple provinces in China and its upcoming integration of advanced health management systems, the acquisition can potentially generate robust revenue streams.
Analysts should note that FuWang anticipates steady revenue growth, projecting revenues of $11.03 million in 2025 growing to $17.24 million by 2027, with corresponding net profits increasing from $1.10 million to $1.72 million in the same period. Such financial forecasts highlight a promising outlook that aligns with Shineco’s growth objectives.
Investors may find relevant investment opportunities in Shineco following this strategic acquisition. However, it's essential to remain cautious and consider the company's execution risk and market competition. Shineco’s ability to successfully integrate FuWang's operations and capitalize on its proprietary technologies will be critical.
The shares may present a compelling buy, particularly if the broader market conditions for the healthcare sector remain stable and favorable. Long-term investors should monitor Shineco's performance closely, particularly its progress against outlined financial targets and the effectiveness of its integration strategy with FuWang. Overall, this acquisition could mark a pivotal moment for Shineco as it seeks to strengthen its position within the competitive medical device market.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
The Acquisition is Expected to Create Immediate Synergies with the Company’s Existing Medical Device Business
BEIJING, March 25, 2025 (GLOBE NEWSWIRE) -- Shineco, Inc. (“Shineco” or the “Company”; NASDAQ: SISI), a provider of innovative diagnostic medical products and related medical devices, announced today that on March 20, 2025, Shineco Life Science Group Hong Kong Co., Limited (“Shineco Life Science”), a subsidiary of the Company, entered into a Stock Purchase Agreement (“SPA”) with Yi Yang (the “Seller”), for 75% of an equity interest in FuWang (HK) International Company Limited (“FuWang Company”). The Seller is the current and only shareholder of FuWang Company, which specializes in the R&D, manufacturing, and commercialization of medical devices.
Pursuant to the SPA, Shineco Life Science will acquire a 75% equity interest in FuWang Company. In consideration of the acquisition, Shineco Life Science shall pay the Seller approximately US$ 8.8 million in cash, the Company shall issue 3,400,000 shares of the Company’s common stock, and it will transfer the 71.42% equity interest in Dream Partner Limited it holds to the Seller.
FuWang Company specializes in the R&D, production and commercialization of Class II and III medical devices, including biochemical analyzers, patient monitors and mobile medical imaging workstations. FuWang Company holds proprietary intellectual property rights and maintains an extensive sales network across multiple Chinese provinces and municipalities, with a particularly strong market presence in Gansu, Henan, Jiangsu, and Shanxi provinces. FuWang Company plans a strategic expansion into integrated health management, combining preventive health screenings with emergency response systems. Leveraging cloud computing and AI technologies, Fuwang Company aims to establish a seamless pre-hospital to in-hospital critical care network, implementing tiered treatment protocols for life-threatening conditions. According to the Seller, FuWang Company will achieve steady financial growth over the next three years, with revenue targets of US$11.03 million (2025), US$13.79 million (2026) and US$17.24 million (2027). Corresponding net profit goals are set at US$1.10 million (2025), US$1.38 million (2026) and US$1.72 million (2027).
Jennifer Zhan, the CEO of Shineco, commented, “We are enthusiastic about our acquisition of a majority position of FuWang Company for its strategic positioning in the medical devices sector and its sales capabilities and channel management expertise. In addition, FuWang Company’s competitive strengths are expected to create immediate synergies with Shineco’s existing business portfolio, and its distinctive operational capabilities is anticipated to greatly enhance Shineco’s overall financial performance,” Jennifer Zhan concluded.
More complete information of the SPA is set forth in the Form 8-K and its exhibits filed with the Securities and Exchange Commission on March 20, 2025.
About Shineco, Inc.
Shineco Inc. (“Shineco” or the “Company”) aims to ‘care for a healthy life and improve the quality of life’, by providing safe, efficient and high-quality health and medical products and services to society. Shineco, operating through subsidiaries, has researched and developed 33 vitro diagnostic reagents and related medical devices to date, and the Company also produces and sells healthy and nutritious foods. For more information about Shineco, please visit www.biosisi.com/ .
Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements can be identified by terminology such as “may”, “will”, “should”, “could”, “intend”, “expect”, “plan”, “budget”, “forecast”, “anticipate”, “believe”, “estimate”, “predict”, “project”, “potential”, “continue”, “evaluating” or similar words. Forward-looking statements should not be relied upon because they are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Examples of forward-looking statements include, among others, statements we make regarding the innovativeness and market position of our products and services, our competitive strengths, and our expectation that the healthy meals replacement joint venture will be a competitive products in its field. You are cautioned not to rely on any forward-looking statements. Actual results may differ materially from historical results or those indicated by the forward-looking statements as a result of a variety of factors including, but not limited to, risks and uncertainties associated with the Company’s ability to raise additional funding, its ability to maintain and grow its business, variability of operating results, its ability to maintain and enhance its brand, its development and introduction of new products and services, the ability to obtain all necessary regulatory approvals in the jurisdictions where it intends to market and sell its products the successful integration of acquired companies, technologies and assets into its portfolio of products and services, marketing and other business development initiatives, competition in the industry, general government regulations, economic conditions, the impact of the COVID-19 pandemic, dependence on key personnel, the ability to attract, hire and retain personnel who possess the technical skills and experience necessary to meet the requirements of its clients, its ability to protect its intellectual property, its ability to integrate acquisitions and the ability of the acquired companies to achieve the financial projections attributed to them. Shineco encourages you to review other factors that may affect its future results in its filings with the Securities and Exchange Commission. The forward-looking statements in this press release are based only on information currently available to us and speak only as of the date of this press release, and Shineco assumes no obligation to update any forward-looking statements except as required by the applicable rules and regulations.
For more information, please contact:
Shineco,Inc.
secretary@shineco.tech
Mobile: +86-010-68130220
Precept Investor Relations LLC
David J. Rudnick
david.rudnick@preceptir.com
Mobile: +1-646-694-8538
FAQ**
How does Shineco Inc. SISI plan to leverage the specific strengths of FuWang Company to create synergies that enhance its existing medical device portfolio?
What are the expected operational synergies between Shineco Inc. SISI and FuWang Company post-acquisition, especially in the integrated health management sector?
Can Shineco Inc. SISI provide more details on how the acquisition of FuWang Company will impact its revenue and profit goals over the next three years?
What measures will Shineco Inc. SISI take to ensure the successful integration of FuWang Company’s proprietary technologies and intellectual property into its existing product offerings?
**MWN-AI FAQ is based on asking OpenAI questions about Shineco Inc. (NASDAQ: SISI).
NASDAQ: SISI
SISI Trading
-18.91% G/L:
$5.53 Last:
24,594 Volume:
$5.78 Open:
